Xenon Pharmaceuticals (XP0) Stock Overview
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XP0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Xenon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.00 |
| 52 Week High | US$62.00 |
| 52 Week Low | US$29.80 |
| Beta | 0.62 |
| 1 Month Change | -8.11% |
| 3 Month Change | 13.84% |
| 1 Year Change | 66.67% |
| 3 Year Change | 48.26% |
| 5 Year Change | 259.15% |
| Change since IPO | 329.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| XP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.0% | 0.6% | -1.5% |
| 1Y | 66.7% | -2.7% | 4.0% |
Return vs Industry: XP0 exceeded the German Biotechs industry which returned -3.2% over the past year.
Return vs Market: XP0 exceeded the German Market which returned 4.2% over the past year.
Price Volatility
| XP0 volatility | |
|---|---|
| XP0 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: XP0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: XP0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 364 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
Xenon Pharmaceuticals Inc. Fundamentals Summary
| XP0 fundamental statistics | |
|---|---|
| Market cap | €4.90b |
| Earnings (TTM) | -€352.89m |
| Revenue (TTM) | n/a |
Is XP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XP0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$352.49m |
| Gross Profit | -US$352.48m |
| Other Expenses | US$56.71m |
| Earnings | -US$409.19m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XP0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 06:50 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xenon Pharmaceuticals Inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |